Adjuvant progestagens for endometrial cancer.

Area of Science:

• Gynecologic Oncology
• Clinical Pharmacology

Background:

• Endometrial cancer is a common malignancy in women, often diagnosed at early stages.
• Adjuvant progestagen therapy is sometimes recommended after surgery to prevent disease recurrence.

Purpose of the Study:

• To assess the efficacy and safety of adjuvant progestagen therapy in endometrial cancer treatment.
• To determine if progestagen therapy reduces recurrence and improves survival rates.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Searched multiple databases including Cochrane, MEDLINE, and EMBASE up to April 2009.
• Pooled risk ratios (RRs) and hazard ratios (HRs) to compare outcomes.

Main Results:

• Seven RCTs involving 4556 women were analyzed.
• No significant difference in five-year mortality risk between progestagen therapy and control groups (RR = 1.00).
• Progestagen therapy did not significantly impact death from endometrial cancer, cardiovascular disease, or intercurrent conditions; evidence on disease relapse was conflicting.

Conclusions:

• Current evidence does not support the use of adjuvant progestagen therapy for primary endometrial cancer treatment.
• Further research may be needed to clarify potential benefits in specific patient subgroups.